To determine the antimicrobial susceptibility rates for key antimicrobial agents and selective bacterial pathogens in the decade of the 1990s.
METHODS:
Data from 1990 to 2000 from the University of Kentucky Clinical Microbiology Laboratory were analyzed by linear regression analysis to identify agents and pathogens that show a decline in susceptibility. For selected pathogens and antimicrobial agents, predictions were made for further declines in susceptibility for 2005 and 2010.
RESULTS:
Significant declines in susceptibility to selected antimicrobial agents were found for Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pneumoniae. Further declines were predicted for 2005 and 2010.
CONCLUSIONS:
Examination of susceptibility rates over time in a university hospital medical center provides useful data for future planning. In our institution, antimicrobial susceptibility rates have significantly declined during the 1990s for certain antimicrobial agents and bacterial pathogens. We are attempting to change our antimicrobial use patterns through formulary manipulation and clinician education, which may retard or prevent such declines in the future.
WenzelRPEdmondMB. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis2001; 7: 174–7.
4.
GoldHSMoelleringRC. Antimicrobial-drug resistance. N Engl J Med1996; 335: 1445–53.
5.
O'BrienTFPlaMPMayerKHKishiHGilleeceESyvanenM. Intercontinental spread of a new antibiotic resistance gene on an epidemic plasmid. Science1985; 230: 87–8.
6.
ChaixCDurand-ZaleskiIAlbertiCBrun-SuissonC. Control of endemic methicillin-resistant Staphylococcus aureus. JAMA1999; 282: 1745–51.
7.
KlepserMEKlepserDGBrooksJMErnstEJDiekemaHLHoffmanHL. Examination of healthcare resource utilization associated with the treatment of infections caused by susceptible (S) and non-susceptible (NS) isolates of Streptococcus pneumoniae (SPN) (abstract 2133). Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000.
8.
Caballero-GranadoFJBecerrilBCuberosLBernabeuMCisnerosJMPachonJ. Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia. Clin Infect Dis2001; 32: 587–94.
9.
Mekontso-DessapAKirschMBrun-BuissonCLoisanceD. Poststernotomy mediastinitis due to Staphylococcus aureus: Comparison of methicillin-resistant and methicillin-susceptible cases. Clin Infect Dis2001; 32: 877–83.
10.
LindenPKPasculleAWManexRKramerDJFungJJPinnaAD. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis1996; 24: 530–1.
11.
Institute of Medicine. Antimicrobial resistance: issues and options (workshop report). Washington, DC: National Academy Press, 1998.
12.
McGowanJECarletJ. Antimicrobial resistance: A worldwide problem for health care institutions. Am J Infect Control1998; 26: 541–3.
13.
ZinnerSH. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria. Clin Infect Dis1999; 29: 490–4.
14.
Centers for Disease Control/National Nosocomial Infections Surveillance System. Selected antimicrobial resistant pathogens associated with nosocomial infections in intensive care unit patients, comparison of resistance rates from January—November, 1998, with 1993–1997. 1999 Report. Atlanta: Centers for Disease Control and Prevention, 1999.
15.
IbrahimEHShermanGWardSFraserVJKollefMH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest2000; 118: 146–55.
16.
Centers for Disease Control and Prevention. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendation for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol1995; 16: 105–13.
17.
NCCLS. 2000. Methods for dilution for antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard — Fifth edition. M7-A5. No. 2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
18.
NCCLS. 2000. Performance standards for antimicrobial disk susceptibility tests; approved standard — Seventh edition. MA-A7. Vol. 20, No. 1. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
19.
NCCLS. 2001. Performance standards for antimicrobial susceptibility testing; eleventh information supplement. M100-S11. Vol. 21, No. 1. Wayne, PA: National Committee for Clinical Laboratory Standards, 2001.
20.
WatererGWWunderinkRG. Increasing threat of gram-negative bacteria. Crit Care Med2001; 29:(suppl 4): N75–81.
21.
GiamarellouHAntoniadouA. Antipseudomonal antibiotics. Med Clin North Am2001; 85: 19–42.
22.
KohlerTPechereJCPlesiatP. Bacterial antibiotic efflux systems of medical importance. Cell Mol Life Sci1999; 56: 771–8.
23.
EvansMEFeolaDJRappRP. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother1999; 33: 960–7.
24.
AmyesSGBMilesRS. Extended-spectrum β-lactamases: The role of inhibitors in therapy. J Antimicrob Chemother1998; 42: 415–7.
25.
GalesACJonesRNTurnidgeJRennieRRamphalR. Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program. Clin Infect Dis2001; 32 (suppl 2):S146–55.
26.
DuboisVArpinCMelonMMelonBAndreCFrigoC. Nosocomial outbreak due to multiresistant strain of Pseudomonas aeruginosa P12: Efficacy of cefepime—amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol2001; 39: 2072–8.
27.
RiceLB. Successful interventions for gram-negative resistance to extended-spectrum β-lactam anbitiotics. Pharmacotherapy1999; 19 (Suppl):120S–8S.
28.
PattersonJEHardinTCKellyCACarciaRCJorgensenJH. Association of antibiotic utilization measures and contol of multiple-drug resistance in Klebsiella pneumoniae. Infect Cont Hosp Epidemiol2000; 21: 455–8.
29.
MonnetDLBiddleJWEdwardsJRCulverDHTolsonJSMartoneWJ. Evidence of interhospital transmission of extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in the United States, 1986–1993. The National Nosocomial Infections Surveillance System. Infect Control Hosp Epidemiol1997; 18: 492–8.
30.
PatersonDLKoWCVon GottbergACasellasJMMulazimogluLKlugmanKP. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol2001; 39: 2206–12.
31.
SandersWESandersCC. Enterobacter spp.: Pathogens poised to flourish at the turn of the century. Clin Microbiol Rev1997; 10: 220–41.
32.
SandersWESandersCC. Inducible beta-lactamases: Clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis1988; 10: 830–8.
33.
PatersonDLSinghNRihsJDSquierCRihsBLMuderRR. Control of an outbreak of infection due to extended-spectrum beta-lactamase—producing Escherichia coli in a liver transplantation unit. Clin Infect Dis2001; 33: 126–8.
Wong-BeringerA. Therapeutic challenges associated with extended-spectrum, beta-lacatamase—producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy2001; 21: 583–92.
36.
DaumRSSealJB. Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: Our backs to the wall. Crit Care Med2001; 29 (suppl 4):N92–6.
37.
MedeirosAA. Beta-lactamases. Br Med Bull1984; 40: 18–27.
38.
FridkinSKStewardCDEdwardsJRPryorERMcGowanJEArchibaldLK. Surveillance of antimicrobial use and antimicrobial resistance in United States hospital: Project ICARE Phase 2. Clin Infect Dis1999; 29: 245–52.
39.
Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep1999; 48: 707–10.
40.
DiekemaDJPfallerMASchmitzFJSmayevskyJBellJJonesRN. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis2001; 32 (suppl 2):S114–32.
41.
TanabeFSatoTNozawaANihonmatsuHImafukuYOgataM. The properties and mec A gene of the methicillin-resistant Staphylococcus aureus isolated in Fukushima Medical College Hospital. Fukushima J Med Sci1993; 39: 35–42.
42.
JonesRLBallowCHBiedenbachDJDeinhartJASchentagJJ. Antimicrobial activity of quinupristin—dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diag Microbiol Infect Dis1998; 31: 437–51.
43.
MarkowitzNQuinnELSaravolatzLD. Trimethoprim—sulfamethoxazole compared to vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med1992; 117: 390–8.
44.
HiramatsuKAritakaNHanakiHKawasakiSHosodaYHoriS. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet1997; 350: 1670–3.
45.
Staphylococcus aureus with reduced susceptibility to vancomycin: Illinois, 1999. MMWR Morb Mortal Wkly Rep2000; 48: 1165–7.
46.
WongSSHoPLWooPCYuenKY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis1999; 29: 760–7.
47.
FridkinSK. Vancomycin-intermediate and resistant Staphylococcus aureus: What the infectious disease specialist needs to know. Clin Infect Dis2001; 32: 108–15.
48.
FileTM. Appropriate use of antimicrobials for drug-resistant pneumonia: Focus on the significance of beta-lactam—resistant Streptococcus pneumoniae. Clin Infect Dis2002; 34 (suppl 1):S17–26.
49.
NCCLS 2001. Performance standards for antimicrobial susceptibility testing: MIC interpretive standard forStreptococcus pneumoniae. 11th Information Supplement. Wayne, PA: Vol. 21: 102.
50.
HobanDJDoernGVFluitACRoussel-DelvallezMJonesRN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis2001; 32 (suppl 2):S81–93.
